Xiaoke Pill lowered hypoglycemia risk with similar HbA1c control
Key takeaway:
In adults with type 2 diabetes and poor glycemic control, Xiaoke Pill lowered hypoglycemia risk compared with glibenclamide while delivering similar HbA1c improvement over 48 weeks.
Study at a glance
Study type
RCTs
duration
Medium-Term (3–12 mo)
Intervention
Xiaoke, Glibenclamide
Outcomes
Hypoglycemia events, HbA1c, Fasting Plasma Glucose, Serious adverse events incidence, Hypoglycemia events, HbA1c, Fasting Plasma Glucose, Serious adverse events incidence
Funding
Industry sponsored
What was studied
Whether Xiaoke Pill can match glibenclamide for glucose control with less hypoglycemia
What they found
- Hypoglycemia events ↓ with Xiaoke Pill compared with glibenclamide
- HbA1c ↓ similarly in both treatment arms
- Fasting plasma glucose ↓ similarly in both treatment arms
- Serious adverse events ↔ none were reported
mainEffects
Hypoglycemia events ↓ with Xiaoke Pill compared with glibenclamide
HbA1c ↓ similarly in both treatment arms
Fasting plasma glucose ↓ similarly in both treatment arms
Serious adverse events ↔ none were reported
Evidence Suggest
- In the drug-naive group, Xiaoke Pill lowered the odds of any hypoglycemia by 38% and mild hypoglycemia by 41% versus glibenclamide.
- In the metformin group, Xiaoke Pill lowered the annual hypoglycemia rate by 62% compared with glibenclamide.
- HbA1c fell by 0.70% with Xiaoke Pill and 0.66% with glibenclamide in the drug-naive group, and by 0.45% versus 0.59% in the metformin group.
- No serious adverse event was reported during the 48-week trial.
Who this applies to
These findings apply most directly to adults aged 21 to 70 with type 2 diabetes, poor glycemic control, and either no prior glucose-lowering drugs or stable metformin use. The results are less certain for non-Chinese populations, people with advanced complications, or those using insulin or other modern drug combinations.
Keep in Mind
Xiaoke Pill was compared with glibenclamide alone, not with newer diabetes treatments. The trial supports similar glucose lowering and fewer hypoglycemia episodes, but it does not prove that the herbal components improve long-term complications. Treatment decisions should still consider access, safety monitoring, and whether sulfonylurea therapy is appropriate in the first place.
Between the Lines
- All participants were treated in China, so generalizability may be limited.
- The study used an active comparator, not a placebo-only herbal control.
- Xiaoke Pill already contains glibenclamide, so the herbal effect cannot be isolated fully.
- Some secondary outcomes were subgroup-based or not fully detailed in the main text.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Sources
Standards of Care in Diabetes—2024
Type 2 diabetes in adults: management
Mayo Clinic - Type 2 Diabetes Treatment Options
Dapagliflozin-induced integrated improvements in left ventricular diastole, endothelial function, and arterial load: a randomized clinical trial.
The serum protein responses to treatment with Xiaoke Pill and Glibenclamide in type 2 diabetes patients.
A functional medicine approach to diabetes control and quality of life: an open-label randomized pilot study.
Pharmacist Intervention for Safer Prescribing in Patients With Type 2 Diabetes at High Risk: A Randomized Clinical Trial.
No ads. No tracking
A clean, privacy-first research experience.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.